Ashwagandha (Withania somnifera) has drawn attention as a candidate for managing sexual side effects of selective serotonin reuptake inhibitors (SSRIs). The interest is driven by three factors: the sexual dysfunction produced by SSRIs is common and chronically undertreated, ashwagandha has accumulated a small but suggestive evidence base for sexual function in non-SSRI contexts, and its safety profile in short-term use is more favorable than most of the pharmacologic alternatives. The relevant question is whether the existing evidence supports using it for SSRI-induced sexual dysfunction specifically, which is a narrower claim than “ashwagandha improves sexual function in general.”
The answer, based on what is currently published, is that the evidence for ashwagandha in SSRI-induced sexual dysfunction specifically is thin, but the evidence in adjacent populations is suggestive enough that a trial is reasonable in selected patients who have not responded to more established approaches.
What SSRI-Induced Sexual Dysfunction Actually Is
Sexual dysfunction is the most common under-reported SSRI side effect. Prevalence estimates in clinical studies range from roughly 30% to 60% of patients on SSRIs for at least several weeks, with higher figures when structured questionnaires are used rather than passive reporting. The phenotype includes reduced libido, delayed or absent orgasm, genital anesthesia, and erectile dysfunction.
The mechanism is not fully characterized. Increased serotonergic tone at 5-HT2A and 5-HT2C receptors inhibits sexual response at multiple levels; reduced dopaminergic activity contributes; nitric oxide availability may be affected. The symptoms typically emerge within weeks of starting the SSRI and persist for the duration of treatment. In a subset of patients, the dysfunction persists after discontinuation — post-SSRI sexual dysfunction (PSSD) — which is a distinct syndrome and is not what ashwagandha is being considered for here.
What Ashwagandha Does
Ashwagandha is an adaptogenic herb with a complex phytochemical profile, including withanolides (the standardized marker compounds), sitoindosides, and alkaloids. Its mechanisms of action are not reducible to a single receptor or pathway. Effects that may be relevant to sexual function include:
HPA axis modulation. Reductions in cortisol with regular dosing are among the more consistent findings in ashwagandha trials; stress-mediated suppression of sexual function may respond.
Testosterone effects. Small studies in men report modest increases in serum testosterone with standardized ashwagandha extracts over 8 to 16 weeks. The magnitude varies and the clinical significance is debated.
Nitric oxide and vascular function. Preclinical data suggest ashwagandha may improve endothelial function, which is relevant to erectile physiology.
Anxiolytic and mood effects. Multiple randomized trials show reductions in anxiety scale scores with ashwagandha; whether this translates to sexual function improvement is less clear, but performance anxiety is a contributor to sexual dysfunction in some patients.
What the Specific Evidence Shows
Studies of ashwagandha in sexual function fall into several groups.
In healthy or infertile men, several small randomized trials have shown improvements in sperm parameters, testosterone, and self-reported sexual function after 8 to 12 weeks of standardized extract at doses typically 500 to 675 mg daily. The effect sizes are modest and the trials are short. Notable examples include work by Ambiye and colleagues (2013), Mahdi and colleagues (2011), and subsequent research groups.
In women with hypoactive sexual desire disorder or general sexual dysfunction not attributed to SSRIs, a small randomized trial by Dongre and colleagues (2015) showed improvement on structured sexual function scales with ashwagandha versus placebo over 8 weeks.
In SSRI-induced sexual dysfunction specifically, well-designed trials are sparse. The evidence is predominantly inferential — applying the adjacent-population data to this indication. Patient-reported experience and some open-label series suggest benefit, but the controlled data at the specific SSRI intersection are not yet adequate to make a confident recommendation.
Comparison to Better-Studied Interventions
For context, the interventions for SSRI-induced sexual dysfunction with the strongest evidence are bupropion augmentation (typically around 150 mg daily added to the SSRI), switching to bupropion or mirtazapine (agents with lower rates of sexual dysfunction), and phosphodiesterase-5 inhibitors for erectile dysfunction specifically. Drug holidays have been studied with mixed results and are generally not recommended for SSRIs with short half-lives. Dose reduction, when clinically feasible, sometimes resolves the problem.
These approaches have larger trials and are the first-line options. Ashwagandha enters the decision tree when these have failed or are not appropriate, or when the patient specifically prefers an herbal intervention.
Practical Considerations
If a trial of ashwagandha is pursued, several details matter.
Standardization. Not all ashwagandha supplements are equivalent. KSM-66 and Sensoril are the two most frequently studied standardized extracts, at daily doses around 300 to 600 mg for most indications. Unstandardized root powder preparations vary in withanolide content and produce less predictable results.
Duration. The studies showing sexual function effects generally ran 8 to 16 weeks. Two-week trials are not long enough to assess response.
Safety monitoring. Ashwagandha is well tolerated in the short-term studies available, but there are case reports of hepatotoxicity, and the herb has thyroid-stimulating effects that can be problematic in patients with hyperthyroidism or on thyroid replacement. Baseline and follow-up thyroid function is reasonable in longer trials.
Interactions. No major pharmacokinetic interaction with SSRIs is established; theoretical serotonergic interaction is mild. Concurrent use is generally considered acceptable, but clinical monitoring remains appropriate.
Pregnancy. Ashwagandha is not recommended in pregnancy.
What a Reasonable Trial Looks Like
For a patient on an SSRI with bothersome sexual dysfunction who has already tried or declined the better-established interventions, a time-limited trial of a standardized ashwagandha extract is not unreasonable. A 12-week trial at a studied dose, with the patient tracking sexual function and mood in a structured way (a validated questionnaire such as the Arizona Sexual Experiences Scale simplifies this), produces a decision point rather than an open-ended commitment. If the response is adequate, continuation is defensible. If it is not, stopping is straightforward.
What this framework does not support is substituting ashwagandha for a proper clinical conversation about the SSRI itself. If the sexual dysfunction is severe enough to drive a patient toward an herbal intervention, it is worth asking whether the SSRI remains the best antidepressant for them, whether the dose can be reduced, and whether a switch would be reasonable. These are the primary clinical questions; ashwagandha is an adjunct within them.